A survey of clinical application of stereotactic radiotherapy technology in China in 2024
10.3760/cma.j.cn113030-20240610-00224
- VernacularTitle:2024年中国立体定向放射治疗技术临床应用情况调查
- Author:
Xiaoxue KOU
1
;
Jiayi YU
;
Jingwei ZHANG
;
Nan BI
;
Xuwei CAI
;
Guanghui CHENG
;
Yufei LU
;
Yanyang WANG
;
Ligang XING
;
Yonggang XU
;
Jianxin XUE
;
Li ZHANG
;
Hongqing ZHUANG
;
Anhui SHI
Author Information
1. 沧州市中心医院胸部肿瘤放疗科，沧州 061001
- Publication Type:Journal Article
- Keywords:
Radiotherapy;
Radiotherapy unit;
Stereotactic body radiation therapy;
Carcinoma, non-small cell lung;
Radiotherapy equipment
- From:
Chinese Journal of Radiation Oncology
2025;34(9):897-904
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the current status of application of stereotactic body radiation therapy (SBRT) in China, aiming to provide reference for promoting the development of this technology.Methods:From January to March 2024, a questionnaire was designed and distributed online, targeting member units of the Professional Committee of Stereotactic Radiosurgery Treatment, which covers 175 radiotherapy units in 30 provinces and regions nationwide. The survey focused on the current application of SBRT technology and its utilization in the treatment of early-stage non-small cell lung cancer (NSCLC). A statistical description of the survey results was presented.Results:Of 175 questionnaires distributed, a total of 130 valid responses were collected, with an effective response rate of 74.3%. A total of 81.5% (106/130) of the units had implemented SBRT technology, and 99.1% of the respondents believed it was necessary to further promote SBRT technology, yet the actual training rate was only 67.0%. SBRT equipment configuration: there were a total of 267 SBRT equipment, featuring a diverse range of types, with traditional linear accelerators as the mainstays, accounting for 76.0% ( n=203), followed by 12.0% ( n=32) for TOMO, 6.4% ( n=17) for Cyber knife, 3.7% ( n=10) for Gamma knife, and proton/heavy ion equipment at 1.5% ( n=4), respectively. The percentage of units with multi-leaf collimator leaf widths ≤0.5 cm was 93.4% (99/106). The application of SBRT: the first radiotherapy unit commenced SBRT in 2000, and this technology entered a period of rapid growth after 2015, sustaining a steady increase over the past decade; SBRT technology was mainly applied in the brain, lung, liver, bone, adrenal gland, and kidney, with application rates of 97.2%, 94.3%, 86.8%, 71.7%, 56.6%, and 27.4%, respectively, while the application rates for the pancreas, metastatic lymph nodes, and other parts were less than 5%. Current status of SBRT technology application in early-stage NSCLC: 90.6% (96/106) of units had implemented SBRT; pre-treatment multi-disciplinary diagnosis and treatment accounted for 77% (74/96); the proportion of application units for peripheral and central type lung cancer lesions both exceeded 57.3%, whereas the application rate for ultra-central type and lesions > 5 cm lung cancer was less than 30%; there was significant variability in the selection of reference guidelines, dose fractionation patterns, and the concept of central type among units. Conclusions:The development of SBRT technology in China is in a period of steady growth, but several issues such as low training rate and lack of standardization still exist. The survey results provide important reference for clinical training and promotion of SBRT technology in China.
